Patients in the YO group with variant KRAS tumors showed significantly higher CSS subdistribution hazards for CRC-related death compared with patients with wild-type KRAS tumors (sHR, 1.09 [95%CI 1.01-1.18]; P = .03) (Figure 3). This evidence concerns the gene KRAS and colorectal carcinoma.